Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine
- Development stage
- Phase 3
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The omicron-delta recombinant novel coronavirus protein vaccine is a protein subunit COVID-19 vaccine candidate designed to provide immunity against SARS-CoV-2 by incorporating spike proteins from both the Delta and Omicron variants of the virus[3][4]. The spike protein in this vaccine is a hybrid, containing characteristic amino acids from both Delta and Omicron parental strains, with a breakpoint between the N-terminal domain and receptor-binding domain of the S1 subunit[2][8]. This design aims to broaden immune protection by targeting mutations present in both major variants. The primary mechanism involves stimulating an immune response—particularly neutralizing antibodies—against these variant-specific spike proteins. The developer of this candidate is Anhui Zhifei Longcom[3].
- Other names
- Omicron-Delta Recombinant Novel Coronavirus Protein VaccineOmicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine.